Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Loomis Sayles, an investment management company, released its “International Growth Fund” third quarter 2024 investor letter.

European stocks were higher on Friday, as markets in the region reopened following a closure for the Christmas holiday.

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

周五，BMO Capital Markets调整了对诺和诺德公司（NYSE:NVO）股票的目标价，将其从156.00美元下调至105.00美元。尽管目标价大幅下调，但该公司仍维持对这家医疗保健公司股票的"优于大市"评级。

Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...